Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1973 Apr;3(4):469–473. doi: 10.1128/aac.3.4.469

Pharmacokinetics of the Aminoglycoside Antibiotic Tobramycin in Humans

Kurt G Naber 1,2, Silvia R Westenfelder 1,2, Paul O Madsen 1,2
PMCID: PMC444436  PMID: 4208290

Abstract

The pharmacokinetics, distribution, and plasma and renal clearance of a new aminoglycoside antibiotic, tobramycin, was studied in the treatment of 18 elderly male patients (average age, 69 years) with urinary tract infections. Ten of these patients had normal renal function and eight had impaired renal function of various degrees. After administration of 1 mg of tobramycin/kg of body weight every 6 to 8 h (two to three times the half-life), urine concentrations were found to be sufficient in the treatment of urinary tract infections caused by susceptible organisms. The renal clearance of tobramycin during constant intravenous infusion was also studied in eight patients. Good correlation was found between the patients serum creatinine and the half-life of tobramycin. The half-life of tobramycin in patients with normal renal function (serum creatine [Formula: see text] to 1.5 mg/100) was on the average 3 h. For practical purposes, therefore, the dosage of tobramycin in the treatment of urinary tract infections should be 1 mg/kg of body weight every 6 to 8 h in patients with normal renal function. For patients with impaired renal function, the dosage interval is calculated by multiplying the patients' serum creatinine by six. If the dosage intervals are kept unchanged, the dosage must be divided by the patients' serum creatinine. The initial loading dose should always be 1 mg/kg. The total renal clearance of tobramycin (92% of the glomerular filtration rate) was not influenced by the administration of probenecid, which indicates that tobramycin is excreted only by glomerular filtration.

Full text

PDF
469

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black H. R., Griffith R. S. Preliminary studies with nebramycin factor 6. Antimicrob Agents Chemother (Bethesda) 1970;10:314–321. [PubMed] [Google Scholar]
  2. Cutler R. E., Gyselynck A. M., Fleet W. P., Forrey A. W. Correlation of serum creatinine concentration and gentamicin half-life. JAMA. 1972 Feb 21;219(8):1037–1041. [PubMed] [Google Scholar]
  3. Cutler R. E., Orme B. M. Correlation of serum creatinine concentration and kanamycin half-life. Therapeutic implications. JAMA. 1969 Jul 28;209(4):539–542. [PubMed] [Google Scholar]
  4. Dienstag J., Neu H. C. In vitro studies of tobramycin, an aminoglycoside antibiotic. Antimicrob Agents Chemother. 1972 Jan;1(1):41–45. doi: 10.1128/aac.1.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Higgins C. E., Kastner R. E. Nebramycin, a new broad-spectrum antibiotic complex. II. Description of Streptomyces tenebrarius. Antimicrob Agents Chemother (Bethesda) 1967;7:324–331. [PubMed] [Google Scholar]
  6. Preston D. A., Wick W. E. Preclinical assessment of the antibacterial activity of nebramycin factor 6. Antimicrob Agents Chemother (Bethesda) 1970;10:322–327. [PubMed] [Google Scholar]
  7. Sabath L. D., Casey J. I., Ruch P. A., Stumpf L. L., Finland M. Rapid microassay for circulating nephrotoxic antibiotics. Antimicrob Agents Chemother (Bethesda) 1970;10:83–90. [PubMed] [Google Scholar]
  8. Sigman E. M., Elwood C. M., Knox F. The measurement of glomerular filtration rate in man with sodium iothalamate 131-I (Conray). J Nucl Med. 1966 Jan;7(1):60–68. [PubMed] [Google Scholar]
  9. Smith H. W., Finkelstein N., Aliminosa L., Crawford B., Graber M. THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. J Clin Invest. 1945 May;24(3):388–404. doi: 10.1172/JCI101618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Stark W. M., Hoehn M. M., Knox N. G. Nebramycin, a new broad-spectrum antibiotic complex. I. Detection and biosynthesis. Antimicrob Agents Chemother (Bethesda) 1967;7:314–323. [PubMed] [Google Scholar]
  11. TILLSON E. K., SCHUCHARDT G. S., FISHMAN J. K., BEYER K. H. The determination of probenecid (benemid) in body fluids. J Pharmacol Exp Ther. 1954 Aug;111(4):385–394. [PubMed] [Google Scholar]
  12. WALSER M., DAVIDSON D. G., ORLOFF J. The renal clearance of alkali-stable inulin. J Clin Invest. 1955 Oct;34(10):1520–1523. doi: 10.1172/JCI103204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wick W. E., Welles J. S. Nebramycin, a new broad-spectrum antibiotic complex. IV. In vitro and in vivo laboratory evaluation. Antimicrob Agents Chemother (Bethesda) 1967;7:341–348. doi: 10.1128/AAC.7.3.341. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES